Key Highlights
- George W. Mahaffey appointed as CEO of Corsair Pharma, bringing over 35 years of experience in pharmaceuticals and biotech.
- Corsair’s transdermal patch promises consistent treprostinil delivery, potentially overcoming current treatment challenges in PAH.
- Expertise in PAH: Mahaffey’s experience includes launching Ventavis®, a prostacyclin product, aligning with Corsair’s focus on PAH.
Source: Business Wire
Notable Quotes
- “The potential for transdermal delivery of a treprostinil prodrug may provide physicians and patients with new treatment options that address PAH patients’ need for safety, efficacy, and convenience.” – George W. Mahaffey, CEO at Corsair Pharma
- “PAH is a devastating disease where there is a clear need for new treatment options offering a meaningful improvement in quality of life for patients suffering with this disease.” – Ivan Gergel, M.D., Managing Partner at New Rhein Healthcare
SoH's Take
The appointment of George W. Mahaffey as CEO of Corsair Pharma signifies a significant stride in the fight against pulmonary arterial hypertension (PAH). His extensive experience in launching innovative treatments like Ventavis® aligns perfectly with Corsair’s pioneering approach to PAH therapy. The development of their transdermal treprostinil prodrug, aiming to provide a more convenient and effective treatment option, could potentially revolutionize the standard of care for PAH. This aligns with the increasing demand for treatments that not only prolong life but also enhance the quality of life for PAH patients. Corsair Pharma’s innovative approach could be a game-changer in a market projected to grow substantially by 2028, marking an exciting era in PAH treatment.
